drugset / Trial / NCT07033689

Feasibility Study of Suizenji, in Patients With Unresectable Pancreatic Ductal Adenocarcinoma (SUNRISE-II)

NCT07033689

Phase 0 Recruiting 10 enrolled SONIRE Therapeutics Inc.
NaSingle-groupOpen-labelDevice feasibility

Summary

This is a feasibility, safety, tolerability, and efficacy research study of an investigational device called "Suizenji", an ultrasound-guided high-intensity focused ultrasound (HIFU) therapy system for the treatment of unresectable pancreatic ductal adenocarcinoma. Focused ultrasound therapy uses a number of small ultrasound generators attached to a bowl-shaped ultrasound generator to emit ultrasound waves from outside to inside the body and focus them on a single point where cancerous cells in the pancreas are located. The targeted area is then heated, which kills the pancreatic cancer cells, and as a result, the patient's life may be prolonged. Experience with Suizenji for pancreatic cancer patients has shown that the "heating" is only a warm feeling in the abdomen during the treatment.

Timeline

Start
2026-01-05
Primary completion
2026-12-01
Completion
2027-03-01

Drugs

EvaluationDrugModalityDoseRoute
Background FL Unknown
Background Gem Unknown
Background Irinotecan Sucrosofate Other / unclassified
Background Nab-PTX Unknown